What one share of Candel Therapeutics holds
We are a clinical stage biopharmaceutical company focused on developing off-the-shelf viral immunotherapies that elicit an individualized, systemic anti-tumor immune response to help patients fight cancer. Our engineered viruses are designed to induce a systemic anti-tumor response due to induction of immunogenic cell death within the tumor microenvironment, thus releasing tumor neo-antigens and creating a pro-inflammatory microenvironment at the site of injection.
Candel Therapeutics’s numbers from its SEC filings, divided by its shares. Results cover the last 12 months to 2026-06-30; the balance sheet is as of 2026-06-30.
| Profit | −$1.47 |
|---|---|
| Capex (buildings and equipment) | $0.02 |
| Free cash flow | −$0.95 |
| Cash and investments | $2.65 |
| Debt | $0.61 |
| Book value | $1.66 |
Per share by fiscal year
| Year | Sales | Profit | Capex | Free cash | Dividends | Book value |
|---|---|---|---|---|---|---|
| 2020 | $0.01 | −$1.52 | $0.13 | −$0.91 | — | −$2.03 |
| 2021 | $0.01 | −$1.91 | $0.10 | −$1.27 | — | $2.24 |
| 2022 | $0.00 | −$0.65 | $0.04 | −$1.14 | — | $1.65 |
| 2023 | — | −$1.31 | $0.02 | −$1.20 | — | $0.44 |
| 2024 | — | −$1.74 | $0.00 | −$0.85 | — | $1.42 |
| 2025 | — | −$0.72 | $0.01 | −$0.73 | — | $0.95 |
Common questions about Candel Therapeutics
How much does one share of Candel Therapeutics earn?
Over the last 12 months, Candel Therapeutics lost $1.47 for each share.
Does Candel Therapeutics pay a dividend?
Candel Therapeutics didn’t pay a dividend over the last 12 months, according to its SEC filings.
What is Candel Therapeutics’s book value per share?
Candel Therapeutics’s book value is $1.66 per share: what would be left for each share if it sold everything at the values on its books and paid every debt, as of June 30, 2026.
How much cash and debt does each share of Candel Therapeutics have?
Each share of Candel Therapeutics has $2.65 of cash and investments and $0.61 of debt, as of June 30, 2026.
What is Candel Therapeutics’s free cash flow per share?
−$0.95 per share over the last 12 months. Free cash flow is the cash left over after spending on buildings and equipment.
Has Candel Therapeutics bought back shares?
Candel Therapeutics’s share count rose about 356% from 2020 to 2025. That dilution means each share owns a smaller slice of the company.
From its SEC filings. For education only, not investment advice. New to these words? See the StockSlicer glossary.